When Dr. Gaurav Kharya returned to India in 2014, he was determined to transform cancer treatment in his home country. Armed with experience from prestigious institutions such as Newcastle University and Imperial College London, Kharya was frustrated by the disparity in cancer care between India and the West. This led to the founding of Cellogen Therapeutics alongside Dr. Tanveer Ahmad. The startup aims to make advanced cancer therapies more affordable and accessible in India.
### Cellogen’s Breakthrough in Cancer Treatment
Cellogen Therapeutics is innovating with its third-generation CAR-T cell therapy, targeting the persistent issue of relapse in blood cancers. CAR-T therapy involves re-engineering a patient’s own immune cells to target and destroy cancer cells. This bespoke approach to cancer treatment is at the core of Cellogen’s mission.
Unlike existing therapies that focus solely on the CD19 antigen, Cellogen’s solution targets both CD19 and CD20 antigens. This dual-target approach addresses the phenomenon of antigen escape, where cancer cells evade treatment by masking a single antigen. By focusing on two markers, Cellogen aims to reduce the likelihood of relapse, which currently affects 50-60% of patients within five years of treatment.
Cellogen’s lead product, XenCAR-T, utilizes a proprietary lentiviral vector platform to ensure that engineered cells persist in the body, hunting cancer cells for years rather than months. This advancement could significantly improve patient outcomes if successful in clinical trials.
### The Competitive Landscape
The global CAR-T therapy market is predominantly led by biotech giants in the US and Europe. Companies like Novartis and Gilead have been at the forefront, with treatments costing upwards of $500,000 per patient. India, with its vast population and increasing cancer incidence, presents a unique opportunity to develop cost-effective solutions.
Cellogen’s focus on affordability and accessibility is critical in a country where high treatment costs often deter patients from seeking advanced care. The startup is positioning itself as a domestic leader in the next-generation cell therapy space, potentially altering the competitive dynamics in the Indian biotech sector.
### Implications for India’s Startup Ecosystem
Cellogen’s progress illustrates the growing potential of India’s biotech sector, particularly in high-impact areas like cancer treatment. As the country seeks to establish itself as a hub for innovative medical solutions, startups like Cellogen are crucial in driving this transformation.
The rise of healthtech startups in India is supported by a robust investment ecosystem, with venture capitalists increasingly interested in biotech innovations. However, challenges remain, including regulatory hurdles and the need for substantial R&D investment. Cellogen’s success could pave the way for more biotech startups to emerge, contributing to a vibrant and competitive landscape.
Looking ahead, Cellogen’s journey will be closely watched by investors and healthcare professionals alike. The startup’s ongoing clinical trials will be a critical milestone in determining the viability of its third-generation CAR-T therapy. Success could not only validate Cellogen’s approach but also set a precedent for affordable, cutting-edge cancer care in India. For founders and investors, this represents a promising opportunity to be part of a transformative movement in Indian healthcare, with potential implications for global biotech innovation.
